United Kingdom · Question · Written question
UIN 201609
Voluntary Scheme for Branded Medicines Pricing and Access
Original
Introduced
13 October 2023
Last action
20 October 2023 · Answer
Status
Answered
Sponsors
—
Subjects
Discovery layer
Source updated
20 October 2023
Summary
To ask the Secretary of State for Health and Social Care, whether he plans to refer the Impact Assessment for the 2023 statutory scheme to control the cost of branded health services medicines to the Regulatory Policy Committee.
This text is taken from the official record. PoliticalRepo does not editorialize.
Timeline
13 October 2023
Written question
To ask the Secretary of State for Health and Social Care, whether he plans to refer the Impact Assessment for the 2023 statutory scheme to control the cost of branded health services medicines to the Regulatory Policy Committee.
Source: Commons
20 October 2023
Answer
There are no plans to refer the statutory scheme Impact Assessment to the Regulatory Policy Committee. The proposals only impact companies which choose to sell to the National Health Service and are therefore considered to be in connection with procuremen...
Source: Written answer
Votes
No vote records are attached yet.
Versions
No version snapshots stored. Document URLs remain at the source.
Documents
No documents linked.
Sponsors
- · Department of Health and Social Care · Answering body
Related records
No cross-record relationships stored yet.
Sources
PoliticalRepo is an index and interpretation layer, not the authoritative legal source.
- Official source: https://questions-statements.parliament.uk/written-questions/detail/2023-10-13/201609
- Open data entity: https://questions-statements-api.parliament.uk/api/writtenquestions/questions/1663756
- uk · wq-1663756 · source updated 20 October 2023